The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Open accessAbstract
In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strong evidence supports the ef fi cacy and cost-effectiveness of nutrition therapy as a component of quality diabetes care, including its integration into the medical management of diabetes”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [2]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,014
Greenwood, D. A., Blozis, S. A., Young, H. M., Nesbitt, T. S., & Quinn, C. C. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4112 · Cited by 128
On behalf of the EMPA-REG EXTEND™ MONO investigators, Roden, M., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H. J., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0314-0 · Cited by 128
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 128
Strain, W. D., Hope, S. V., Green, A., Kar, P. S., Valabhji, J., & Sinclair, A. J. (2018) · Diabetic Medicine · doi:10.1111/dme.13644 · Cited by 128
2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Budzynski, A. Z., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., Dziedzic, T., Franek, E., et al. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0001 · Cited by 128
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
DPP-4 Inhibition and the Path to Clinical Proof
Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 127
Nauck, M. A., Stewart, M. W., Perkins, C., Jones-Leone, A. R., Yang, F., Perry, C., Reinhardt, R. R., & Rendell, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3795-1 · Cited by 126
Self-citationPharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 126
Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0529-3 · Cited by 126
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
Hadjadj, S., Rosenstock, J., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-0522 · Cited by 122
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 122
Kanasaki, K. (2018) · Clinical Science · doi:10.1042/cs20180031 · Cited by 121
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
Adipose Tissue: Physiology to Metabolic Dysfunction
Richard, A. J., White, U. A., Elks, C. M., & Stephens, J. M. (2020) · Europe PMC (PubMed Central) · Cited by 118
Shared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Alam, F., Islam, M. A., Mohamed, M., Ahmad, I., Kamal, M. A., Donnelly, R., IDRIS, I. R., & Gan, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41854-2 · Cited by 117
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease
Kwon, S., Kim, Y. C., Park, J. Y., Lee, J., An, J. N., Kim, C. T., Oh, S., Park, S., Kim, D. K., Oh, Y. K., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0936 · Cited by 116
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 117
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Kalra, S., Aamir, A., Raza, A., Das, A., Khan, A. A., Shrestha, D., Qureshi, M., Fariduddin, M., Pathan, M. F., Jawad, F., et al. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163171 · Cited by 114
Physical activity and exercise on diabetic foot related outcomes: A systematic review
Matos, M., Mendes, R., Silva, A. B., & Sousa, N. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.020 · Cited by 114
Mendes, R., Sousa, N., Themudo-Barata, J. L., & Reis, V. M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16214163 · Cited by 114
Barazzoni, R., Deutz, N. E. P., Biolo, G., Bischoff, S., Boirie, Y., Cederholm, T., Cuerda, C., Delzenne, N., Leon Sanz, M., Ljungqvist, O., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.010 · Cited by 112
Ali, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Shivashankar, R., Ajay, V. S., Unnikrishnan, A. G., Menon, V. U., Varthakavi, P. K., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2807 · Cited by 114
Shared Decision-Making in Diabetes Care
Tamhane, S. U., Rodríguez‐Gutiérrez, R., Hargraves, I. G., & Montori, V. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0688-0 · Cited by 113
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Tohma, H., Altay, A., Köksal, E., Gören, A. C., & Gülçın, İ. (2019) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-019-00077-9 · Cited by 111
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 110
Users’ acceptability of a mobile application for persons with type 2 diabetes: a qualitative study
Torbjørnsen, A., Ribu, L., Rønnevig, M., Grøttland, A., & Helseth, S. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4486-2 · Cited by 110
Giagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
Scheen, A. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215427 · Cited by 109
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 108
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 108
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 108
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells
Yang, X., Xu, Z., Zhang, C., Cai, Z., & Zhang, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.019 · Cited by 108
Exenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 107
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106
Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Hiroi, S., Onishi, Y., Guelfucci, F., & Shimasaki, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025806 · Cited by 106
Rehman, M. B., Tudrej, B. V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Vaillant-Roussel, H., Gueyffier, F., Faillie, J., Pérault-Pochat, M.-C., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.09.005 · Cited by 105
Huang, Y., Shiyanbola, O. O., & Smith, P. D. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s153312 · Cited by 105
Lu, C., Chiang, J., Tsai, F., Hsu, Y., Juan, Y., Yang, J., & Chiu, H. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4704 · Cited by 105
Manivannan, A., Lee, E.-S., Han, K., Lee, H., & Kim, D. (2020) · Molecules · doi:10.3390/molecules25225258 · Cited by 104
Li, T., Providencia, R. A., Mu, N., Yin, Y., Chen, M., Wang, Y., Liu, M., Yu, L., Gu, C., & Ma, H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01202-5 · Cited by 105
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102
Self-citationDungan, K. M., Weitgasser, R., Manghi, F. P., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 102
Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
Peralta, F. G., Dunn, T. C., Landuyt, K., Xu, Y., & Merino-Torres, J. F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001052 · Cited by 101
Pasternak, B., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1186 · Cited by 102
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 103
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.144 · Cited by 101
Gomes, M. B., Rathmann, W., Charbonnel, B. H., Khunti, K., Kosiborod, M., Nicolucci, A., Pocock, S., Shestakova, M. V., Shimomura, I., Tang, F., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.024 · Cited by 101
Future glucose-lowering drugs for type 2 diabetes
Bailey, C. J., Tahrani, A. A., & Barnett, A. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00462-3 · Cited by 100
Personalized medicine in diabetes: the role of ‘omics’ and biomarkers
Pearson, E. R. (2016) · Diabetic Medicine · doi:10.1111/dme.13075 · Cited by 100
Bain, S. C., Mosenzon, O., Arechavaleta, R., Bogdański, P., Çömlekçi, A., Consoli, A., Deerochanawong, C., Dungan, K. M., Faingold, M. C., Farkouh, M. E., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13553 · Cited by 100
Self-citationPharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 102
Jabbour, S. A., Frías, J. P., Hardy, E., Ahmed, A., Wang, H., Öhman, P., & Guja, C. (2018) · Diabetes Care · doi:10.2337/dc18-0680 · Cited by 99
Şöhretoğlu, D., Sarı, S., Barut, B., & Özel, A. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.05.010 · Cited by 99
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Seidu, S., Kunutsor, S. K., Topsever, P., Hambling, C. E., Cos, F. X., & Khunti, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13724 · Cited by 97
Pantalone, K. M., Wells, B. J., Chagin, K. M., Ejzykowicz, F., Yu, C., Milinovich, A., Bauman, J. M., Kattan, M. W., Rajpathak, S. N., & Zimmerman, R. S. (2016) · Diabetes Care · doi:10.2337/dc16-0227 · Cited by 97
Gourgari, E., Wilhelm, E. E., Hassanzadeh, H. R., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 97
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Bækdal, T. A., Thomsen, M., Kupčová, V., Hansen, C. W., & Anderson, T. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1131 · Cited by 97
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 96
Kar, D., Gillies, C., Zaccardi, F., Webb, D. R., Seidu, S., Tesfaye, S. H., Davies, M. J., & Khunti, K. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0475-5 · Cited by 96
Management of diabetes in older adults
Sesti, G., Incalzi, R. A., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 96
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 95
Hansen, M., Scheltema, M. J. V., Sonne, D. P., Hansen, J. S., Sperling, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12648 · Cited by 95
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Cinti, F., Moffa, S., Impronta, F., CEFALO, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114932 · Cited by 94
The pharmacogenetics of metformin
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4335-y · Cited by 95
Update on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Rosenthal, N., Meininger, G. E., Ways, K., Polidori, D., Desai, M. G., Qiu, R., Alba, M., Vercruysse, F., Balis, D. A., Shaw, W. C., et al. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12852 · Cited by 93
Dennis, J., Shields, B. M., Hill, A. V., Knight, B., McDonald, T. J., Rodgers, L. R., Weedon, M. N., Henley, W., Sattar, N. A., Holman, R. R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1827 · Cited by 92
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 92
Dludla, P. V., Muller, C. J. F., Joubert, E., Louw, J., Essop, M. F., Gabuza, K., Ghoor, S., Huisamen, B., & Johnson, R. (2017) · Molecules · doi:10.3390/molecules22010129 · Cited by 92
Semaglutide: review and place in therapy for adults with type 2 diabetes
Goldenberg, R. M., & Steen, O. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.05.008 · Cited by 91
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12589 · Cited by 91
Self-citationMata‐Cases, M., Franch‐Nadal, J., Real, J., & Mauricio, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012463 · Cited by 91
Aging and Cardiovascular Disease: Current Status and Challenges
Zhou, M., Zhao, G., Zeng, Y., Zhu, J., Cheng, F., & Liang, W. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304135 · Cited by 91
Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review
Minari, T. P., Tácito, L. H. B., Yugar, L. B. T., Ferreira‐Melo, S. E., Manzano, C. F., Pires, A. C., Moreno, H., Vilela-Martin, J. F., Cosenso‐Martin, L. N., & Yugar‐Toledo, J. C. (2023) · Nutrients · doi:10.3390/nu15245096 · Cited by 91
Metformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 91
Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
Nie, X., Chen, Z., Pang, L., Wang, L., Jiang, H., Chen, Y., Zhang, Z., Fu, C., Ren, B., & Zhang, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s285134 · Cited by 90
Alam, F., Islam, M. A., Kamal, M. A., & Gan, S. H. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160813222436 · Cited by 90
Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V., & Mendivil, C. O. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0374-8 · Cited by 90
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 89
Bongaerts, B. W. C., Müssig, K., Wens, J., Lang, C., Schwarz, P. E. H., Roden, M., & Rathmann, W. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013076 · Cited by 89
Stem-cell based organ-on-a-chip models for diabetes research
Rogal, J., Zbinden, A., Schenke‐Layland, K., & Loskill, P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.010 · Cited by 89
Rosenstock, J., Diamant, M., Aroda, V. R., Silvestre, L., Souhami, E., Zhou, T., Perfetti, R., Fonseca, V. A., & for the LixiLan PoC Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0046 · Cited by 89
Self-citationMiller, S. S., Krumins, T., Zhou, H., Huyck, S. B., Johnson, J. R., Golm, G. T., Terra, S. G., Mancuso, J. P., Engel, S. S., & Lauring, B. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0358-0 · Cited by 88
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 88
Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis
Ren, C., Liu, W., Li, J., Cao, Y., Xu, J., & Lu, P. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01319-4 · Cited by 88
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 89
Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis
Gasmi, A., Peana, M., Arshad, M., Butnariu, M., Menzel, A., & Bjørklund, G. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-02974-9 · Cited by 88
Sinclair, A. J., Bode, B., Harris, S., Vijapurkar, U., Shaw, W., Desai, M., & Meininger, G. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14028 · Cited by 87
Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2941 · Cited by 87
Current management of diabetes mellitus and future directions in care
Chatterjee, S., & Davies, M. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133200 · Cited by 87
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- American Cancer Society (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-13
- Volume
- 38
- Issue
- 1
- Pages
- 140-149
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2160088494
- Cited by
- 3,066
- References
- 68
- Citations by year
- 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
- FWCI
- 380.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Massachusetts General Hospital
- Yale University
- Kaiser Permanente
- F. Hoffmann-La Roche
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- Intarcia Therapeutics
- National Institute for Health and Care Research
- University of Sydney
- Universiteit van Amsterdam
- University of Toronto
- Novo Nordisk
- Uniwersytet Łódzki
- European Association for the Study of Diabetes
- Université de Nantes
- Servier
- Lilly Deutschland
- University of Ioannina
- School of Medicine, University of Kansas
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
